An interventional study of Metformin 30% Topical Lotion and Minoxidil 5 % Topical Spray in Alopecia Areata(AA), sponsored by Sohag University. Recruiting at 1 site in Egypt. Open to participants aged 18 Years to 40 Years. Per ClinicalTrials.gov, last updated 2026-11-19.
Sponsored by Sohag University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Alopecia Areata with a site in Egypt — 8 open to participants now, 9 under way, none of them phase 3. Alopecia Areata · Egypt.
Among the 32 studies in Alopecia Areata with a site in Egypt, this one is the 10th largest by planned enrollment of the 30 interventional ones that give a count, is the only one that started in 2026, is one of 15 with no phase, and was the 32nd registered.
221 studies on the registry are indexed under Alopecia Areata; 62 are open to participants now.
Browse Alopecia Areata studies →8 of the 32 studies in Alopecia Areata with a site in Egypt are open now. Recruiting first, the newest first:
Egymedicalpedia · Sites in Egypt
Ages 30–35
Zagazig University · Sites in Egypt
Ages 16+
Sohag University · Sites in Egypt
Ages 4+
Assiut University · Sites in Egypt
Ages 6–60
Al-Azhar University · Sites in Egypt
Ages 12+
A study can be open while its sites in Egypt have not opened yet or have stopped. Only those recruiting at a site in Egypt →
Of the 42 Alopecia Areata studies recruiting now, 17 (40%) set no upper age limit and 21 (50%) stop at 75 or younger; 20 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 40 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 3 · Phase 4 6
First in 2012; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 60 is above the median of 50 across 171 interventional studies indexed under Alopecia Areata.
Median enrollment 50 across the 30 interventional studies, 120 across the 2 observational. Of the 15 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 32 have an industry lead sponsor. The 10 most frequent:
Sohag University is the lead sponsor of 1,236 studies on the registry; 639 are open to participants now.
Sohag University has 7 studies filed under Alopecia Areata — fewer than ten, so there is no comparison to draw.
3 of the studies in Alopecia Areata with a site in Egypt that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06327581Zagazig UniversityCombined Microneedling With Either 1% Lactic Acid Solution or Vitamin D3 or Triamcinolone Acetonide in The Treatment of Alopecia Areata | 2026-12-30 |
| NCT06399783Assiut UniversityTopical Simvastatin Versus Topical Steroid in Treatment of Alopecia Areata | 2027-10-01 |
| NCT07947992Sohag UniversityEfficacy of Topical Metformin 30% Versus Minoxidil 5% in the Treatment of Alopecia Areata : Comparative Study | 2027-11-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Alopecia Areata with a site in Egypt, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study aims to evaluate and compare the effectiveness and safety of topical metformin 30% and topical minoxidil 5% in patients with alopecia areata.
Alopecia areata is an autoimmune condition that causes non-scarring hair loss, usually presenting as round or oval patches on the scalp. Different topical treatments are used to stimulate hair regrowth, but their effectiveness varies.
In this comparative interventional study, eligible patients with alopecia areata will receive either topical metformin 30% or topical minoxidil 5%. Treatment response will be assessed clinically during follow-up using standardized assessment methods, including the Severity of Alopecia Tool (SALT) score, along with clinical and dermoscopic evaluation.
The study aims to determine whether topical metformin 30% is an effective treatment option compared with topical minoxidil 5% in patients with alopecia
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to this arm will receive topical metformin 30% for the treatment of alopecia areata.
Drug: Metformin 30% Topical Lotion
Participants assigned to this arm will receive topical minoxidil 5% for the treatment of alopecia areata.
Drug: Minoxidil 5 % Topical Spray
Topical metformin 30% preparation used for the treatment of alopecia areata.
Topical minoxidil 5% preparation used for the treatment of alopecia areata.
Change in SALT Score from Baseline to Week 12
Assessment of the change in Severity of Alopecia Tool (SALT) score from baseline to week 12 to evaluate the therapeutic response to topical metformin 30% compared with topical minoxidil 5%. A decrease in SALT score indicates improvement in scalp hair loss.
Time frame: Baseline to Week 12 (12 weeks)
Plan to share: No
No publications or documents are linked to this record.
Started Oct 2026 (actual). Primary completion is estimated for Nov 2027, 12 months after the start.
Of 21 interventional studies with no phase under Alopecia Areata, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 24. This study's planned 12 months is close to that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.